Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hikma Pharmaceuticals PLC (HKMPF)
London, GB
Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded products, licensed drugs, and generic formulations. These pharmaceutical offerings come in various forms, such as solids, semi-solids, liquids, and injectables. The company's operations are divided into three core segments: Injectables, which primarily supplies generic injectable medications to hospitals; Generics, focusing on oral and other non-injectable generic drugs for the retail market; and Branded, which provides both proprietary generics and in-licensed pharmaceuticals to retail consumers and healthcare institutions. Hikma's product portfolio addresses a broad spectrum of medical needs, spanning anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory disorders. Founded in 1978 and based in London, United Kingdom, the company extends its reach across the UK, the United States, the Middle East, North Africa, Europe, and other international markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.02% | +10.20% | +10.81% | -2.94% | -4.75% | -28.07% | -13.28% | -42.85% | -37.47% | +238.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+9.5% ★ Q4'25: +17.5% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+14.9% Q4'25: +174.1% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.1% Q4'25: +6.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.6% ★ Q4'25: +18.0% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.8% ★ Q4'25: +23.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.93× Q4'25: 1.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 1 EPS Ana. |
Dec 2027 9 Rev. Ana. 1 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 4 Rev. Ana. 1 EPS Ana. |
Dec 2030 4 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.44B
est: 1.45B (-0.7%)
|
1.95B
est: 1.94B (+0.7%)
|
1.94B
est: 1.94B (+0.0%)
|
2.07B
est: 2.09B (-1.1%)
|
2.21B
est: 2.18B (+1.3%)
|
2.34B
est: 2.33B (+0.4%)
|
2.55B
est: 2.51B (+1.7%)
|
2.52B
est: 2.49B (+0.9%)
|
2.88B
est: 2.85B (+0.9%)
|
3.13B
est: 3.09B (+1.3%)
|
3.42B
est: 3.33B (+2.9%)
|
3.46B
3.43B – 3.51B
+4.2% YoY
|
3.63B
3.57B – 3.71B
+4.7% YoY
|
3.80B
3.75B – 3.86B
+4.7% YoY
|
4.00B
3.95B – 4.06B
+5.2% YoY
|
4.17B
4.12B – 4.24B
+4.4% YoY
|
| EBITDA |
459.00M
est: 410.97M (+11.7%)
|
506.00M
est: 548.87M (-7.8%)
|
554.00M
est: 548.82M (+0.9%)
|
527.00M
est: 593.50M (-11.2%)
|
584.00M
est: 617.55M (-5.4%)
|
796.28M
est: 661.03M (+20.5%)
|
705.00M
est: 712.00M (-1.0%)
|
691.00M
est: 706.99M (-2.3%)
|
791.00M
est: 808.06M (-2.1%)
|
787.00M
est: 819.09M (-3.9%)
|
854.59M
est: 882.70M (-3.2%)
|
919.62M
911.42M – 930.42M
+4.2% YoY
|
962.68M
948.34M – 984.33M
+4.7% YoY
|
1.01B
996.07M – 1.03B
+4.7% YoY
|
1.06B
1.05B – 1.08B
+5.2% YoY
|
1.11B
1.09B – 1.13B
+4.4% YoY
|
| EBIT |
393.00M
est: 320.63M (+22.6%)
|
401.00M
est: 428.22M (-6.4%)
|
-687.00M
est: 428.18M (-260.4%)
|
428.00M
est: 463.03M (-7.6%)
|
486.00M
est: 481.80M (+0.9%)
|
652.37M
est: 515.72M (+26.5%)
|
561.00M
est: 555.49M (+1.0%)
|
498.00M
est: 551.58M (-9.7%)
|
619.00M
est: 630.43M (-1.8%)
|
608.00M
est: 625.62M (-2.8%)
|
637.88M
est: 674.21M (-5.4%)
|
702.41M
696.15M – 710.66M
+4.2% YoY
|
735.31M
724.35M – 751.84M
+4.7% YoY
|
770.03M
760.80M – 783.30M
+4.7% YoY
|
810.02M
800.32M – 823.98M
+5.2% YoY
|
845.39M
835.27M – 859.97M
+4.4% YoY
|
| Net Income |
252.00M
est: 281.55M (-10.5%)
|
155.00M
est: 216.03M (-28.2%)
|
-843.00M
est: 199.20M (-523.2%)
|
282.00M
est: 288.57M (-2.3%)
|
486.00M
est: 322.50M (+50.7%)
|
431.00M
est: 378.63M (+13.8%)
|
421.00M
est: 429.83M (-2.1%)
|
188.00M
est: 393.93M (-52.3%)
|
190.00M
est: 458.78M (-58.6%)
|
359.00M
est: 487.84M (-26.4%)
|
410.94M
est: 499.00M (-17.6%)
|
492.90M
485.23M – 503.95M
-1.2% YoY
|
542.54M
534.09M – 554.70M
+10.1% YoY
|
584.84M
575.73M – 597.95M
+7.8% YoY
|
630.72M
620.90M – 644.85M
+7.8% YoY
|
790.53M
778.22M – 808.25M
+25.3% YoY
|
| SGA |
352.00M
est: 290.22M (+21.3%)
|
429.00M
est: 387.61M (+10.7%)
|
474.00M
est: 387.57M (+22.3%)
|
467.00M
est: 419.12M (+11.4%)
|
487.00M
est: 436.11M (+11.7%)
|
482.88M
est: 466.81M (+3.4%)
|
488.00M
est: 502.81M (-2.9%)
|
509.00M
est: 499.26M (+2.0%)
|
632.00M
est: 570.64M (+10.8%)
|
568.00M
est: 594.88M (-4.5%)
|
578.59M
est: 641.08M (-9.7%)
|
667.89M
661.94M – 675.74M
+4.2% YoY
|
699.17M
688.75M – 714.89M
+4.7% YoY
|
732.19M
723.42M – 744.81M
+4.7% YoY
|
770.22M
760.99M – 783.49M
+5.2% YoY
|
803.85M
794.22M – 817.71M
+4.4% YoY
|
| EPS |
1.27
est: 1.26 (+0.8%)
|
0.67
est: 0.97 (-30.7%)
|
-3.51
est: 0.89 (-493.8%)
|
1.17
est: 1.29 (-9.4%)
|
2.01
est: 1.44 (+39.3%)
|
1.83
est: 1.69 (+8.0%)
|
1.82
est: 1.92 (-5.4%)
|
0.84
est: 1.76 (-52.3%)
|
0.85
est: 2.05 (-58.6%)
|
1.62
est: 2.19 (-26.1%)
|
1.86
est: 2.24 (-17.0%)
|
2.21
2.18 – 2.26
-1.2% YoY
|
2.44
2.40 – 2.49
+10.1% YoY
|
2.63
2.59 – 2.69
+7.8% YoY
|
2.83
2.79 – 2.90
+7.8% YoY
|
3.55
3.49 – 3.63
+25.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mazen Samih Taleb Darwazeh | Executive Vice Chairman & Deputy CEO of MENA | 2M | male |
| Said Samih Taleb Darwazah | Chief Executive Officer | 2M | — |
| Khalid Walid Hussni Al Nabilsi | Deputy CEO of North America and Europe & Director | 43.5K | male |
| Hussein Arkhagha | Chief People Officer | — | male |
| Julie Hill | Senior Vice President of Corporate Quality Compliance/Health & Safety | — | female |
| Patricia Bousfield | Chief Information Officer | — | female |
| Samuel Park | General Counsel | — | male |
| Areb KURDI | VP, Group Financial Controller & Acting CFO | — | male |
| Susan Ringdal | Executive Vice President of Strategic Planning & Global Affairs | — | female |
| Bassam Wael Rushdi Kanaan | Executive Vice President of Corporate Development and M&A | — | male |
| Guy Featherstone | Associate Director of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HKMPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
